Disorders of the central nervous system cognitive and mnestic functions in genetic arterial hypertension and with the use of beta-blockers of different generations
DOI:
https://doi.org/10.14739/mmt.2024.3.310996Keywords:
hypertension, cognitive functions, beta-blockers, propranolol, carvedilol, hypertrilAbstract
Arterial hypertension is currently one of the most common diseases in the world. A long-term increase in pressure results in changes in the target organs, the healthy functioning of which depends on a stable blood supply (kidneys, eyes, brain), which is primarily caused by damage to small vessels. β-blockers are among the drugs with proven effectiveness in the treatment of hypertension, but their long-term use has different effects on the cognitive sphere, which is determined by the coordination of neurotrophic and neurotransmitter processes in the corresponding brain structures.
Aim. To comparatively analyze the effect of β-blockers from different generations on cognitive and memory functional parameters of the central nervous system in rats with genetically determined hypertension.
Materials and methods. The study used 40 male rats weighing 280–300 g with spontaneous arterial hypertension (SHR) aged 8 months and 10 normotensive control normotensive Wistar–Kyoto rats (WKR) weighing 200–220 g. The animals were divided into 5 experimental groups of 10 rats each. In the experimental study, massometric, instrumental, functional and statistical methods were used with triple measurement of blood pressure by non-invasive Blood Pressure Analysis Systems TM BP-2000 Series II (Visitech Systems, USA). SHR of the 3rd, 4th, and 5th groups were orally administered drugs daily for 30 days, propranolol – 50 mg/kg, carvedilol – 50 mg/kg, and hypertril – 20 mg/kg, respectively. The ability of animals to learn and remember an aversive stimulus was assessed through the conditioned passive avoidance reaction. test Statistical data processing was performed by the package of applied and statistical programs Excel 7.0 (Microsoft Corp., USA) and Statistica (license No. JPZ804I382130ARCN10-J). The significance of differences in study results was determined by pSt ≤ 0.05.
Results. In groups of rats that received β-blockers with different properties (groups 3, 4 and 5), blood pressure was quickly stabilized to target values. A comparative analysis of the cognitive parameters after correction by β-blockers of different generations has shown a significant difference in their effects with proven high effectiveness of hypertril. The drug increased the latency to enter the dark chamber 24 hours after training compared to animals treated with propranolol (group 3) by almost 3-fold, with a 4-fold increase in the percentage of trained animals. The advantages of carvedilol were a 54 % longer latent period and a 2-fold greater number of rats that successfully developed the reflex. Correction with propranolol and carvedilol has proven to be poorly effective in terms of the ability to learn and develop the conditioned-reflex skill with the worst effect of propranolol.
Conclusions. Rats with spontaneous arterial hypertension (SHR) demonstrate a significant decrease in cognitive performance compared to normotensive rats. Drug correction of arterial hypertension with hypertril (a β-blocker of the latest generation with NO-mimetic action) has a highly effective effect on the development of conditioned-reflex skills and the ability to learn that indicates a reduction in cognitive deficits in SHR with essential arterial hypertension.
References
Pallarés-Carratalá V, Ruiz-García A, Serrano-Cumplido A, Arranz-Martínez E, Divisón-Garrote JA, Moyá-Amengual A, et al. Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study. Medicina (Kaunas). 2023;59(10):1846. doi: https://doi.org/10.3390/medicina59101846
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-37. doi: https://doi.org/10.1038/s41581-019-0244-2
Nguyen TN, Chow CK. Global and national high blood pressure burden and control. Lancet. 2021;398(10304):932-3. doi: https://doi.org/10.1016/S0140-6736(21)01688-3
Furdela V, Pavlyshyn H, Kovalchuk T, Haliyash N, Luchyshyn N, Kozak K, et al. Prevalence of arterial hypertension among Ukrainian students: the comparison of European and American guidelines. Pediatr Endocrinol Diabetes Metab. 2022;28(2):123-31. doi: https://doi.org/10.5114/pedm.2022.112859
Sanders AE, Schoo C, Kalish VB. Vascular Dementia. 2023 Oct 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. PMID: 28613567.
Melchiorri D, Merlo S, Micallef B, Borg JJ, Dráfi F. Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? Front Pharmacol. 2023;14:1196413. doi: https://doi.org/10.3389/fphar.2023.1196413
Bakoyiannis I, Ducourneau EG, Parkes SL, Ferreira G. Pathway specific interventions reveal the multiple roles of ventral hippocampus projections in cognitive functions. Rev Neurosci. 2023;34(7):825-38. doi: https://doi.org/10.1515/revneuro-2023-0009
Rotella JA, Greene SL, Koutsogiannis Z, Graudins A, Hung Leang Y, Kuan K, et al. Treatment for beta-blocker poisoning: a systematic review. Clin Toxicol (Phila). 2020;58(10):943-83. doi: https://doi.org/10.1080/15563650.2020.1752918
Anderson ND. State of the Science on Mild Cognitive Impairment. J Gerontol B Psychol Sci Soc Sci. 2020;75(7):1359-60. doi: https://doi.org/10.1093/geronb/gbaa040
Soldan A, Pettigrew C, Cai Q, Wang J, Wang MC, Moghekar A, et al. Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease. Neurobiol Aging. 2017;60:164-72. doi: https://doi.org/10.1016/j.neurobiolaging.2017.09.002
Wang T, Mao L, Wang J, Li P, Liu X, Wu W. Influencing Factors and Exercise Intervention of Cognitive Impairment in Elderly Patients with Chronic Obstructive Pulmonary Disease. Clin Interv Aging. 2020;15:557-66. doi: https://doi.org/10.2147/CIA.S245147
Ran LS, Liu WH, Fang YY, Xu SB, Li J, Luo X, et al. Alcohol, coffee and tea intake and the risk of cognitive deficits: a dose-response meta-analysis. Epidemiol Psychiatr Sci. 2021;30:e13. doi: https://doi.org/10.1017/S2045796020001183
Stavrinou PS, Andreou E, Aphamis G, Pantzaris M, Ioannou M, Patrikios IS, et al. The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment. Nutrients. 2020;12(2):325. doi: https://doi.org/10.3390/nu12020325
Correia RR, Veras AS, Tebar WR, Rufino JC, Batista VR, Teixeira GR. Strength training for arterial hypertension treatment: a systematic review and meta-analysis of randomized clinical trials. Sci Rep. 2023;13(1):201. doi: https://doi.org/10.1038/s41598-022-26583-3
Dybiec J, Krzemińska J, Radzioch E, Szlagor M, Wronka M, Młynarska E, et al. Advances in the Pathogenesis and Treatment of Resistant Hypertension. Int J Mol Sci. 2023;24(16):12911. doi: https://doi.org/10.3390/ijms241612911
Bludorn J, Railey K. Hypertension Guidelines and Interventions. Prim Care. 2024;51(1):41-52. doi: https://doi.org/10.1016/j.pop.2023.07.002
Cojocariu SA, Maștaleru A, Sascău RA, Stătescu C, Mitu F, Leon-Constantin MM. Neuropsychiatric Consequences of Lipophilic Beta-Blockers. Medicina (Kaunas). 2021;57(2):155. doi: https://doi.org/10.3390/medicina57020155
Holm H, Ricci F, Di Martino G, Bachus E, Nilsson ED, Ballerini P, et al. Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. Vascul Pharmacol. 2020;125-126:106649. doi: https://doi.org/10.1016/j.vph.2020.106649
Beaman EE, Bonde AN, Larsen SM, Ozenne B, Lohela TJ, Nedergaard M, et al. Blood-brain barrier permeable β-blockers linked to lower risk of Alzheimer's disease in hypertension. Brain. 2023;146(3):1141-51. doi: https://doi.org/10.1093/brain/awac076
Yang W, Luo H, Ma Y, Si S, Zhao H. Effects of Antihypertensive Drugs on Cognitive Function in Elderly Patients with Hypertension: A Review. Aging Dis. 2021;12(3):841-851. doi: https://doi.org/10.14336/AD.2020.1111
Yao J, Chen SR. R-carvedilol, a potential new therapy for Alzheimer's disease. Front Pharmacol. 2022;13:1062495. doi: https://doi.org/10.3389/fphar.2022.1062495
Abdullah Shamim M, Yeung S, Shahid A, Chen M, Wang J, Desai P, et al. Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption. Int J Pharm. 2022;611:121302. doi: https://doi.org/10.1016/j.ijpharm.2021.121302
Mazur I, Belenichev I, Kucherenko L, Bukhtiyarova N, Puzyrenko A, Khromylova O, et al. Antihypertensive and cardioprotective effects of new compound 1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril). Eur J Pharmacol. 2019;853:336-44. doi: https://doi.org/10.1016/j.ejphar.2019.04.013